Bioanalytical Systems reports net gain of $252.

This comes even close to a net reduction for fiscal 2012 of $6,317,000, or $0.88 per diluted and basic talk about, including a pre-tax reduction in the fair worth of the warrant liability of $73,000. EBITDAR for fiscal 2013 risen to $2,785,000, in comparison to an EBITDAR lack of $118,000 for fiscal 2012.. Bioanalytical Systems reports net gain of $252,000 for fourth quarter 2013 Bioanalytical Systems, Inc. today announced monetary results for the 4th quarter and fiscal 2013, highlighted by net gain of $252,000, or $0.03 per diluted talk about, for the fourth quarter and $773,000, or $0.09 per diluted share, for the full year. This comes even close to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per talk about, for the fourth quarter and fiscal 2012.Further evaluation of this treatment shows that the complete disappearance of the primary tumor happened in about 80 % of patients. More importantly, after two years the same %age of patients remained cancer-free. Considering that the majority of our individuals had stage 4 disease, our efficacy results are far very encouraging thus, said Dr. Argiris. Furthermore, the UPCI investigators mentioned that treatment-related toxicities had been expected and manageable. Dr. Argiris and his colleagues are organizing more clinical research using this routine. While much longer follow-up will become had a need to assess long-term efficacy and side effects, the addition of cetuximab to chemotherapy and radiotherapy is quite promising and could become the standard of treatment in the next few years, stated Dr.

Other entries from category "prevention":

Tag Cloud